AllianceBernstein Holding LP (AB)

20.95
0.00 (0.00)
NYSE : Financial
Prev Close 20.95
Open 20.86
Day Low/High 20.75 / 21.12
52 Wk Low/High 20.40 / 25.12
Volume 1.09M
Avg Volume 440.00K
Exchange NYSE
Shares Outstanding 96.47M
Market Cap 2.02B
EPS 2.20
P/E Ratio 9.74
Div & Yield 1.84 (8.80%)

Latest News

AXA Shares Jump After US IPO Plans Follow Ousting of AllianceBernstein's Peter Kraus

AXA Shares Jump After US IPO Plans Follow Ousting of AllianceBernstein's Peter Kraus

Axa, Europe's second largest. insurer will sell a minority stake in its US operations after ousting AllianceBernstein CEO Peter Kraus.

AllianceBernstein CEO Kraus Fired Along With All Independent Board Members

AllianceBernstein CEO Kraus Fired Along With All Independent Board Members

Peter Kraus becameCEO in 2008.

Analysts' Actions -- Lululemon, L Brands, Masco, Under Armour and More

Analysts' Actions -- Lululemon, L Brands, Masco, Under Armour and More

Here are Wednesday's top research calls, including an upgrade for Lululemon and new coverage of L Brands, Masco and Under Armour.

AB Expands Multi-Asset Solutions Platform With Industry Veteran New Hire

AB Expands Multi-Asset Solutions Platform With Industry Veteran New Hire

Newly-created role supports firm's continued expansion of its multi-asset solutions business driven by client demand for outcome oriented solutions

AB Celebrates 50th Anniversary

AB Celebrates 50th Anniversary

AB Achieves Perfect Score In 2017 Corporate Equality Index

AB Achieves Perfect Score In 2017 Corporate Equality Index

AB Earns 100 percent on Human Rights Campaign Foundation's Fifteenth Annual Scorecard on LGBT Workplace Equality

Beyond Bitcoin: Big Banks Test Out Blockchain Technology

Beyond Bitcoin: Big Banks Test Out Blockchain Technology

Fourteen banks tested blockchain technology in the syndicated loan market, and benefits were seen.

AB Science Announces The Filing Of Masitinib In The Treatment Of Amyotrophic Lateral Sclerosis (ALS) To The European Medicines Agency

AB Science Announces The Filing Of Masitinib In The Treatment Of Amyotrophic Lateral Sclerosis (ALS) To The European Medicines Agency

Filing of masitinib in the treatment of amyotrophic lateral sclerosis (ALS) to the European Medicines Agency (EMA)

AB Secures First Client For Its Multi-Manager Target-Date Collective Investment Trust Portfolios Funding With $340 Million In Assets

AB Secures First Client For Its Multi-Manager Target-Date Collective Investment Trust Portfolios Funding With $340 Million In Assets

Financial Services Client Moves from Passive to Hybrid Solution Including Active Management

Align With AllianceBernstein for Income

Align With AllianceBernstein for Income

This master limited partnership offers high cash payout without taking on undue risk.